PE20110394A1 - Virus sincitial respiratorio vivo atenuado - Google Patents
Virus sincitial respiratorio vivo atenuadoInfo
- Publication number
- PE20110394A1 PE20110394A1 PE2011000971A PE2011000971A PE20110394A1 PE 20110394 A1 PE20110394 A1 PE 20110394A1 PE 2011000971 A PE2011000971 A PE 2011000971A PE 2011000971 A PE2011000971 A PE 2011000971A PE 20110394 A1 PE20110394 A1 PE 20110394A1
- Authority
- PE
- Peru
- Prior art keywords
- protein coded
- gen
- gene
- protein
- glutamic acid
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 17
- 235000018102 proteins Nutrition 0.000 abstract 12
- 102000004169 proteins and genes Human genes 0.000 abstract 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
- 235000013922 glutamic acid Nutrition 0.000 abstract 3
- 239000004220 glutamic acid Substances 0.000 abstract 3
- 239000004471 Glycine Substances 0.000 abstract 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 2
- 235000004279 alanine Nutrition 0.000 abstract 2
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18564—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19832708P | 2008-11-05 | 2008-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110394A1 true PE20110394A1 (es) | 2011-06-22 |
Family
ID=41527812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000971A PE20110394A1 (es) | 2008-11-05 | 2009-11-03 | Virus sincitial respiratorio vivo atenuado |
Country Status (19)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0921424A2 (pt) * | 2008-11-05 | 2016-01-05 | Merck Sharp & Dohme | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. |
| WO2013026054A2 (en) * | 2011-08-18 | 2013-02-21 | Axella Solutions, Llc | Production of infectious rna viruses in yeast |
| US9463236B2 (en) | 2011-08-29 | 2016-10-11 | Tokushima University | RSV mucosal vaccine |
| CA2900713A1 (en) | 2013-02-08 | 2014-08-14 | Steffen Mueller | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
| CN105189756B (zh) * | 2013-03-14 | 2021-06-11 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
| EP3057978B1 (en) | 2013-10-16 | 2022-09-14 | Merck Sharp & Dohme LLC | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
| WO2015057548A1 (en) | 2013-10-16 | 2015-04-23 | Merck Sharp & Dohme Corp | Thermostable respiratory synctial virus (rsv) vaccine compositions |
| US10947512B2 (en) * | 2015-08-14 | 2021-03-16 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered NS1 protein function and related materials and methods |
| SG11201803581VA (en) | 2015-10-29 | 2018-05-30 | Univ Emory | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
| AU2017332789B2 (en) | 2016-09-23 | 2021-05-27 | Codagenix, Inc. | Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes |
| TWI911431B (zh) | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| EP3681523A4 (en) * | 2017-09-15 | 2021-12-29 | The Ohio State Innovation Foundation | Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections |
| AU2024380679A1 (en) * | 2023-11-17 | 2026-07-02 | Sanofi Vaccines US Inc. | Trehalose vaccine formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0917592A4 (en) * | 1996-04-04 | 2002-04-24 | Univ Michigan | REDUCED RSV |
| IL138681A0 (en) | 1998-03-26 | 2001-10-31 | American Cyanamid Co | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
| CN101260386A (zh) | 1999-07-09 | 2008-09-10 | 美国政府健康及人类服务部 | 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产 |
| JP2007531491A (ja) | 2002-09-27 | 2007-11-08 | メディミューン・ヴァクシンズ・インコーポレーテッド | 呼吸器合胞体ウイルスにおける機能的突然変異 |
| WO2004087062A2 (en) * | 2003-03-28 | 2004-10-14 | Medimmune Vaccines, Inc. | Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 |
| KR20090114431A (ko) * | 2007-02-07 | 2009-11-03 | 디나벡크 가부시키가이샤 | 약독화 마이너스 가닥 ｒｎａ 바이러스 |
| BRPI0921424A2 (pt) * | 2008-11-05 | 2016-01-05 | Merck Sharp & Dohme | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. |
-
2009
- 2009-11-03 BR BRPI0921424A patent/BRPI0921424A2/pt not_active IP Right Cessation
- 2009-11-03 RU RU2011122615/10A patent/RU2011122615A/ru not_active Application Discontinuation
- 2009-11-03 CN CN2009801537266A patent/CN102272295A/zh active Pending
- 2009-11-03 AU AU2009311287A patent/AU2009311287C1/en not_active Ceased
- 2009-11-03 WO PCT/US2009/063024 patent/WO2010053883A1/en not_active Ceased
- 2009-11-03 KR KR1020117010304A patent/KR20110063863A/ko not_active Ceased
- 2009-11-03 EP EP09748199.8A patent/EP2346990B1/en active Active
- 2009-11-03 CA CA2742086A patent/CA2742086A1/en not_active Abandoned
- 2009-11-03 US US13/127,647 patent/US9011876B2/en active Active
- 2009-11-03 MX MX2011004719A patent/MX2011004719A/es unknown
- 2009-11-03 JP JP2011534864A patent/JP5016731B2/ja not_active Expired - Fee Related
- 2009-11-03 PE PE2011000971A patent/PE20110394A1/es not_active Application Discontinuation
-
2011
- 2011-04-17 IL IL212437A patent/IL212437A0/en unknown
- 2011-04-19 TN TN2011000182A patent/TN2011000182A1/fr unknown
- 2011-05-04 CL CL2011000999A patent/CL2011000999A1/es unknown
- 2011-05-05 EC EC2011011033A patent/ECSP11011033A/es unknown
- 2011-05-05 ZA ZA2011/03259A patent/ZA201103259B/en unknown
- 2011-05-12 CO CO11058596A patent/CO6362047A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33913A patent/MA32878B1/fr unknown
- 2011-08-05 JP JP2011171459A patent/JP5743794B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL212437A0 (en) | 2011-06-30 |
| EP2346990A1 (en) | 2011-07-27 |
| CN102272295A (zh) | 2011-12-07 |
| CA2742086A1 (en) | 2010-05-14 |
| ECSP11011033A (es) | 2011-12-30 |
| AU2009311287C1 (en) | 2015-02-19 |
| JP5743794B2 (ja) | 2015-07-01 |
| KR20110063863A (ko) | 2011-06-14 |
| JP2011250798A (ja) | 2011-12-15 |
| TN2011000182A1 (en) | 2012-12-17 |
| AU2009311287A1 (en) | 2010-05-14 |
| BRPI0921424A2 (pt) | 2016-01-05 |
| JP5016731B2 (ja) | 2012-09-05 |
| CO6362047A2 (es) | 2012-01-20 |
| ZA201103259B (en) | 2012-01-25 |
| RU2011122615A (ru) | 2012-12-20 |
| MA32878B1 (fr) | 2011-12-01 |
| AU2009311287B2 (en) | 2013-02-07 |
| CL2011000999A1 (es) | 2012-07-20 |
| US9011876B2 (en) | 2015-04-21 |
| WO2010053883A1 (en) | 2010-05-14 |
| JP2012507302A (ja) | 2012-03-29 |
| US20110212130A1 (en) | 2011-09-01 |
| EP2346990B1 (en) | 2016-01-06 |
| MX2011004719A (es) | 2011-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011960A (es) | Peptidos penetradores de celulas. | |
| CO6362047A2 (es) | Virus sincitial respiratorio vivo atenuado | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| WO2018109220A3 (en) | Novel recombinant prefusion rsv f proteins and uses thereof | |
| CL2012000119A1 (es) | Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus. | |
| CY1119265T1 (el) | Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| HRP20160798T1 (hr) | Rekombinantni antigeni iz rsv | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| BRPI0411363A (pt) | seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas | |
| PE20090483A1 (es) | Vectores para la expresion multiple de genes | |
| RU2009119597A (ru) | Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| PE20110106A1 (es) | Peptidos mediadores del eflujo del colesterol mejorados | |
| ATE493497T1 (de) | Verfahren zur herstellung von oligopeptiden | |
| DE602004027362D1 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
| TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
| WO2010057242A3 (de) | Vakzin | |
| RU2013107777A (ru) | Поливалентная вакцина против гриппа на основе гибридного белка | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| RU2010139769A (ru) | Фармацевтическая композиция для трансназального введения | |
| NZ570708A (en) | Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |